Signaling Pathway
Brenetafusp is a monoclonal antibody designed to target both CD3E and PRAME. This dual-targeting approach enhances its potential for use in the selective elimination of tumor cells while engaging the immune system via the CD3E component. Brenetafusp holds significant promise for therapeutic applications in oncology, particularly in treatments aimed at PRAME-expressing malignancies.
重要通知：仅供研究使用。我们不向患者销售。
| Discription | Brenetafusp is a monoclonal antibody designed to target both CD3E and PRAME. This dual-targeting approach enhances its potential for use in the selective elimination of tumor cells while engaging the immune system via the CD3E component. Brenetafusp holds significant promise for therapeutic applications in oncology, particularly in treatments aimed at PRAME-expressing malignancies. |
||
|---|---|---|---|
| Targets |
|
Calculate the dilution required to prepare a stock solution. This equation is commonly abbreviated as: C1V1 = C2V2
